Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review-Reference-Cited by-同舟云学术

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review

Published:2017-02-03 Issue:2 Volume:15 Page:e2000487
ISSN:1545-7885
Container-title:PLOS Biology
language:en
Short-container-title:PLoS Biol

Author:

Mattina James,Carlisle Benjamin,Hachem Yasmina,Fergusson Dean,Kimmelman Jonathan^ORCID

Publisher

Public Library of Science (PLoS)

Subject

General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Reference231 articles.

1. Life cycle of translational research for medical interventions;DG Contopoulos-Ioannidis;Science,2008

2. How to increase value and reduce waste when research priorities are set;I Chalmers;The Lancet,2014

3. Increasing value and reducing waste in research design, conduct, and analysis;JP Ioannidis;The Lancet,2014

4. The prevalence of underpowered randomized clinical trials in rheumatology;HI Keen;The Journal of rheumatology,2005

5. Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials;A Hakala;BMJ,2015

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies;JCO Oncology Practice;2023-12-18

2. Preclinical efficacy in investigator's brochures: Stakeholders' views on measures to improve completeness and robustness;British Journal of Clinical Pharmacology;2022-08-31

3. Preclinical Efficacy in Investigator’s Brochures: Stakeholders’ views on measures to improve Completeness and Robustness;2022-02-08

4. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis;Targeted Oncology;2021-06-10

5. Details of risk–benefit communication in informed consent documents for phase I/II trials;Clinical Trials;2020-11-24